Gossamer Bio Implements 1-for-80 Reverse Stock Split to Meet Nasdaq Listing Requirements
Event summary
- Gossamer Bio's board approved a 1-for-80 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
- The reverse stock split will take effect at 11:59 p.m. ET on September 10, 2026, with trading on a split-adjusted basis beginning September 11, 2026.
- The number of authorized shares of common stock will be reduced from 4 billion to 50 million.
- Fractional shares will be rounded up to the nearest whole share, with no fractional shares issued.
- The conversion rates of outstanding convertible notes, warrants, and equity awards will be proportionately adjusted.
The big picture
Gossamer Bio's reverse stock split is a strategic move to address its low share price and maintain its listing on the Nasdaq. This action reflects broader trends in the biopharmaceutical industry where companies face pressure to meet exchange listing requirements amid volatile market conditions. The split also highlights the company's focus on regulatory compliance and capital structure optimization as it advances its clinical-stage pipeline.
What we're watching
- Market Reaction
- How investors will respond to the reverse stock split and whether it will achieve the desired increase in share price.
- Regulatory Compliance
- Whether the reverse stock split will successfully maintain Gossamer Bio's listing on the Nasdaq Global Select Market.
- Operational Impact
- The potential effects of the reverse stock split on the company's results of operations and business operations.